253 related articles for article (PubMed ID: 25758809)
1. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011.
Kurebayashi J; Miyoshi Y; Ishikawa T; Saji S; Sugie T; Suzuki T; Takahashi S; Nozaki M; Yamashita H; Tokuda Y; Nakamura S
Breast Cancer; 2015 May; 22(3):235-44. PubMed ID: 25758809
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
3. Annual report of the Japanese Breast Cancer Society registry for 2016.
Kubo M; Kumamaru H; Isozumi U; Miyashita M; Nagahashi M; Kadoya T; Kojima Y; Aogi K; Hayashi N; Tamura K; Asaga S; Niikura N; Ogo E; Iijima K; Tanakura K; Yoshida M; Miyata H; Yamamoto Y; Imoto S; Jinno H
Breast Cancer; 2020 Jul; 27(4):511-518. PubMed ID: 32394414
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
5. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
8. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.
Sawaki M; Yamada A; Kumamaru H; Miyata H; Nakayama K; Shimizu C; Miyashita M; Honma N; Taira N; Saji S
Breast Cancer; 2021 Jan; 28(1):1-8. PubMed ID: 33219915
[TBL] [Abstract][Full Text] [Related]
10. Predicting axillary sentinel node status in patients with primary breast cancer.
Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
[TBL] [Abstract][Full Text] [Related]
11. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study.
Kataoka A; Tokunaga E; Masuda N; Shien T; Kawabata K; Miyashita M
Breast Cancer; 2014 Nov; 21(6):643-50. PubMed ID: 23588791
[TBL] [Abstract][Full Text] [Related]
18. [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status].
Hirano A; Shimizu T; Kamimura M; Ogura K; Kim N; Setoguchi Y; Okubo F; Kinoshita J; Ogawa K; Fujibayashi M
Gan To Kagaku Ryoho; 2011 May; 38(5):771-6. PubMed ID: 21566435
[TBL] [Abstract][Full Text] [Related]
19. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
20. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
